Streetbeat News

Price Targets

PHAT

Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Phathom Pharmaceuticals (NASDAQ:PHAT) and maintained a price target of $23.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 8:28 am

IMVT

Raymond James analyst Danielle Brill has upgraded Immunovant (NASDAQ:IMVT) from Market Perform to Outperform and set a price target of $40.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 8:23 am

IONS

Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Ionis Pharmaceuticals (NASDAQ:IONS) and maintained a price target of $60.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 8:16 am

STLD

Over the past 3 months, 7 analysts have published their opinion on Steel Dynamics (NASDAQ:STLD) stock. The company has an average price target of $108.14, an increase of 2.21% from the previous average price target of $105.80. The ratings include 2 bullish, 3 indifferent, and 2 somewhat bearish.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 9:00 pm

DPZ

Oppenheimer analyst Brian Bittner has reiterated an Outperform rating on Domino's Pizza Inc (NYSE:DPZ), raising the price target to $450 from $427. Bittner views DPZ as an under-appreciated revival story into 2024 and has selected it as a top pick. He expects the company to drive positive earnings revisions, validate unit growth restoration, and repair investor sentiment. Bittner anticipates a positive revision cycle to begin in 4Q23 and a healthier algorithm in '24E/25E, with unit growth accelerating to 6%+.

Portfolio Pulse from Nabaparna Bhattacharya

September 26, 2023 | 7:53 pm

FCX

A significant investor has taken a bullish stance on Freeport-McMoRan (NYSE:FCX), with 70% of recent trades being bullish and 30% bearish. The targeted price range for the company over the last 3 months is $30.0 to $55.0. The current price of FCX is down -1.87% at $36.51. Morgan Stanley has maintained their Equal-Weight rating on Freeport-McMoRan, with a price target of $44.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 7:45 pm

MAR

Morgan Stanley analyst Stephen W Grambling has reiterated an Overweight rating on Marriott International Inc (NASDAQ:MAR) with a price target of $225. The company is set to host its first investor day in over four years on September 27. The analyst anticipates a similar structure to previous events, with added details on recent brand launches, partnerships, and technology investments. The company is expected to deliver an 11% 2019-2023 EPS CAGR on +2% RevPAR and +7% EBITDA. The recent sell-off leaves MAR trading at 19x the analyst's 2024 EPS, below the long-term average of ~21.5X.

Portfolio Pulse from Shivani Kumaresan

September 26, 2023 | 7:10 pm

LUV

Southwest Airlines' shares are trading lower after Bernstein maintained a Market Perform rating on the stock but lowered its price target from $32 to $28.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 6:23 pm

ADBE

Unusual options activity has been observed for Adobe (NASDAQ:ADBE), with a split sentiment of 50% bullish and 50% bearish among big-money traders. The total amount for puts is $570,330, and for calls is $1,267,490. The targeted price range for Adobe over the last 3 months is from $340.0 to $575.0. Adobe's stock price is currently down by 1.58% at $503.54. Several financial institutions have maintained their ratings on Adobe, with price targets ranging from $620 to $650.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 5:45 pm

UNH

A significant investor has taken a bearish stance on UnitedHealth Group (NYSE:UNH), with 90% of recent trades being bearish. The price target for the company over the last three months has been between $430.0 and $540.0. The current price of UNH is down -0.87% at $505.83. Cantor Fitzgerald and HSBC have downgraded their actions to Overweight and Hold respectively, with price targets of $591 and $540.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 5:30 pm